GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Retained Earnings

NAMS (NewAmsterdam Pharma Co NV) Retained Earnings : $-558.57 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. NewAmsterdam Pharma Co NV's retained earnings for the quarter that ended in Dec. 2024 was $-558.57 Mil.

NewAmsterdam Pharma Co NV's quarterly retained earnings declined from Jun. 2024 ($-449.75 Mil) to Sep. 2024 ($-466.39 Mil) and declined from Sep. 2024 ($-466.39 Mil) to Dec. 2024 ($-558.57 Mil).

NewAmsterdam Pharma Co NV's annual retained earnings declined from Dec. 2022 ($-140.04 Mil) to Dec. 2023 ($-316.97 Mil) and declined from Dec. 2023 ($-316.97 Mil) to Dec. 2024 ($-558.57 Mil).


NewAmsterdam Pharma Co NV Retained Earnings Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Retained Earnings Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
-7.47 -39.26 -140.04 -316.97 -558.57

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -316.97 -410.74 -449.75 -466.39 -558.57

NewAmsterdam Pharma Co NV Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


NewAmsterdam Pharma Co NV  (NAS:NAMS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


NewAmsterdam Pharma Co NV Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.